Skip to main content
. 2010 Jan 7;49(4):697–705. doi: 10.1093/rheumatology/kep423

Table 2.

Baseline co-morbidity in PsA cases and seronegative RA control cohorts at baseline

Co-morbid disorders Control (n = 1115), n (%) All PsA cohort (n = 596)
n (%) Adjusted ORa (95% CI)
Cardiovascular disorders
    Hypertension 377 (34) 174 (29) 0.96 (0.87, 1.07)
    Angina 93 (8) 9 (2) 0.72 (0.47, 1.11)
    Myocardial infarction 50 (4) 6 (1) 0.64 (0.34, 1.20)
    Stroke 38 (3) 13 (2) 0.79 (0.56, 1.11)
Pulmonary disorders
    Bronchitis and emphysema 13 (1) 6 (1) 1.07 (0.59, 1.93)
    Asthma* 167 (15) 51 (9) 0.80 (0.65, 0.98)
    COPD 98 (9) 26 (4) 0.96 (0.75, 1.22)
Endocrine disorders
    Diabetes 81 (7) 32 (5) 0.97 (0.74, 1.26)
    Hyperthyroidism 44 (4) 8 (1) 0.82 (0.53, 1.26)
GIT disorders
    Peptic ulcer disease 75 (7) 41 (6.88) 1.19 (0.97, 1.46)
    Liver disease 23 (2) 28 (4.70) 1.20 (0.91, 1.56)
    Renal disease 31 (3) 12 (2.01) 0.91 (0.59, 1.40)
CNS disorders
    Demyelination 7 (1) 0 (0)
    Epilepsy 18 (2) 15 (3) 1.02 (0.70, 1.49)
    Depression 195 (17) 114 (19) 1.08 (0.94, 1.23)
Past malignancy 71 (6) 13 (2) 0.70 (0.45, 1.06)

aORs are calculated versus control and adjusted for age, sex and smoking.

*P < 0.05. COPD: chronic obstructive pulmonary disease.